Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
05:05am, Friday, 21'st Jul 2023
Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.
These 13 S&P 500 stocks stand out for expected growth through 2025
10:42am, Thursday, 20'th Jul 2023
As the 2023 stock-market rally continues, this is a good time to look further ahead to see which companies are expected to show the highest growth rates through 2025.
2 Healthcare Stocks That Could Join the $1 Trillion Club by 2033
10:00am, Thursday, 20'th Jul 2023
Eli Lilly and UnitedHealth Group have market caps in excess of $400 billion. Promising weight-loss treatments could generate significant growth for Eli Lilly.
My Take: 4 Strong Growth Stocks to Buy This Week
07:15am, Thursday, 20'th Jul 2023
Eli Lilly's emphasis on diabetes and obesity drugs sets it apart. Royal Caribbean is benefiting as people return to travel experiences.
At-home Alzheimer's testing is on the horizon, researchers say
08:04am, Wednesday, 19'th Jul 2023
A simple blood test of the type that can be done at home by a patient or family member has shown promise in detecting Alzheimer's, according to research released Wednesday at the Alzheimer's Associati
Eli Lilly's Alzheimer's drug slows cognitive decline: Study
05:31pm, Tuesday, 18'th Jul 2023
Yahoo Finance Health Care Reporter Anjalee Khemlani discusses the latest study on the experimental drug, as well as Pfizer's partnership with Flagship Pioneering.
Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression
12:50pm, Tuesday, 18'th Jul 2023
Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.
Biogen, Eli Lilly likely to split the Alzheimer's drug market, analysts say
08:39am, Tuesday, 18'th Jul 2023
Eli Lilly and Co. LLY, -0.52% and Biogen Inc. BIIB, -0.19% are likely to reach an “equitable split” of the Alzheimer's drug market after Lilly on Monday released more details on its late-stage tri
Is It Too Late to Buy Eli Lilly Stock?
05:26am, Tuesday, 18'th Jul 2023
Shares of Eli Lilly have soared 44% since the end of February. Eli Lilly's latest acquisition target was developing a drug that could work alongside Ozempic and related treatments.
Eli Lilly & Co study shows Alzheimer's drug slows memory decline
01:13pm, Monday, 17'th Jul 2023
Eli Lilly & Co revealed on Monday final results from its Phase 3 clinical study of donanemab at the Alzheimer's Association International Conference in Amsterdam, which showed that the antibody treatm
Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patients
01:01pm, Monday, 17'th Jul 2023
David Ricks, Eli Lilly chair and CEO, joins 'Squawk on the Street' to discuss the trial results for the company's Alzheimer's drug, how these results compare to those of Biogen and more.
Eli Lilly Says Alzheimer's Treatment Slows Cognitive Decline
11:00am, Monday, 17'th Jul 2023
A Phase 3 trial shows that Eli Lilly's investigational Alzheimer's treatment donanemab significantly slowed cognitive and functional decline in people in the early stages of the disease.
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
10:15am, Monday, 17'th Jul 2023
Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Eli Lilly's Alzheimer's treatment shows promise in early stages of disease — but safety concerns remain
10:15am, Monday, 17'th Jul 2023
The Eli Lilly and Co. LLY, -0.47% investigational Alzheimer's treatment donanemab has shown particular promise in treating patients at younger ages and in the earliest stage of disease, according to n
Lilly drug slows Alzheimer's by 60% for mildly impaired patients, Alzheimer's group says
10:08am, Monday, 17'th Jul 2023
Eli Lilly's experimental drug donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, the Alzheimer's Association said in a press relea
